Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone

International Clinical Psychopharmacology

Volumn 22, Issue 2, 2007, Pages 85-92

  Schmauss, Max ^a   Sacchetti, Emilio ^b   Kahn, Jean Pierre ^c   Medori, Rossella ^d  

^a Bezirkskrankenhaus Augsburg ^*  (Germany)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Ctr Hospitalier Univ de Nancy   (France)

^d Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

Antipsychotics; Depot injections; Dose; Psychosis; Schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SCHIZOPHRENIA; SHORT FORM 36; SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; BODY WEIGHT; CARDIOVASCULAR SYSTEM; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33846966290     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3280119ddb     Document Type: Article

References (37)

1. Adams CE, Fenton MK, Quraishi S, David AS (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290-299.
2. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E (2003). Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63:493-512.
3. American Psychiatric Association (1994). DSM IV, diagnostic & statistical manual of mental disorders, 4th ed. Washington, District of Columbia: American Psychiatric Association.
4. Babiker IE (1987). Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 48:94-97.
5. Bradford DW, Perkins DO, Lieberman JA (2003). Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 63:2265-2283.
6. Bryden KE, Gardner DM, Kopala LC (2003). First episode psychosis: early intervention strategies with second-generation antipsychotic medications. Int J Clin Pract 57:513-518.
7. Chouinard G, Ross-Chouinard A, Annable L (1980). The extrapyramidal symptom rating scale. Can J Neurol Sci 7:233.
8. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. (2005). Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15:111-117.
9. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47:741-773.
10. DeQuardo JR, Tandon R (1998). Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J Psychiatr Res 32:229-242.
11. Eerdekens M, Van Hove I, Remmerie B, Mannaert E (2004). Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70:91-100.
12. Ehret MJ, Fuller MA (2004). Long-acting injectable risperidone. Ann Pharmacother 38:2122-2127.
13. Ereshefsky L, Mannaert E (2005). Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 6:129-137.
14. Ereshefsky L, Mascarenas CA (2003). Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64 (Suppl 16):18-23.
15. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P, Chrzanowski W, et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257.
16. Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, et al. (2005). Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 8:27-36.
17. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. (2004). Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 161:692-699.
18. Green JH (1988). Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 39:963-966.
19. Guy W (1976). Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Vol. 76 (Rev.). Rockville, Maryland: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs. pp. 218-220.
20. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr, Davis JM, Lewis DA (1995). Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 152:856-861.
21. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36:1283-1294.
22. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8:55-66.
23. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
24. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
25. Lambert M, Conus P, Lambert T, McGorry PD (2003). Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 4:717-750.
26. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ (2005). Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 8:1-12.
27. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M (2004). Safety and efficacy of long-acting risperidone in schizophrenia: a 12-Week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65:1084-1089.
28. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546.
29. Marriott P, Hiep A (1976). A mirror-image outpatient study at a depot phenothiazine clinic. Aust NZ J Psychiatry 10:163-167.
30. McHorney CA, Ware JE Jr, Raczek AE (1993). The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247-263.
31. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E (2005). Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20:121-130.
32. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR (1998). Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm 55 (Suppl 4). S17-S19.
33. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M (2004). Health-related quality of life in patients with schizophrenia during treatment with longacting, injectable risperidone. J Clin Psychiatry 65:531-536.
34. Sullivan G, Wells KB, Morgenstern H, Leake B (1995). Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 152:1749-1756.
35. Swartz M, Swanson J, Wagner H, Burns B, Hiday V (2001). Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. J Nerv Ment Dis 189:583-592.
36. Ware JE Jr, Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483.
37. Weiden PJ, Kozma C, Grogg A, Locklear J (2004). Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatry Serv 55:886-891.